On August 17, WUXI APPTEC rose 3.14% in regular trading, trading at 202.8 HKD/share, with turnover of 3.12 billion HKD. The rally was driven by a recent wave of international banks raising their target prices on the stock, combined with continued positive momentum from a U.S. court ruling and robust earnings.

Multiple major institutions have upgraded their outlooks in recent days. Bank of America raised its H-share target price to 242 HKD from 204.3 HKD, maintaining a Buy rating, citing strong global biotech financing and active license-out transactions boosting CRO/CDMO demand. Daiwa raised its target to 230 HKD, reaffirming the company as its top sector pick, while Citi lifted its target to 215 HKD, noting mid-year results significantly exceeded expectations.

The company earlier secured a preliminary injunction from a U.S. federal court blocking enforcement of the 1260H designation during litigation, marking an initial legal victory that supports overseas order acquisition. First-half revenue reached 28.9 billion yuan, up 38.93% year-over-year, with net profit surpassing 10 billion yuan for the first time, confirming strong fundamental delivery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)